BPMX BioPharmX Corporation. Common

0.42
+0.02  (5.5%)
Previous Close 0.40
Open 0.43
Price To book 0.00
Market Cap 28.58M
Shares 67,719,000
Volume 1,008,232
Short Ratio 0.75
Av. Daily Volume 1,038,750

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated in 2017
BPX-03
Moderate to severe periodic breast pain associated with FBC (fibrocystic breast condition) and cyclic mastalgia
Phase 2b completion of enrollment announced January 4, 2017. Data due 1H 2017.
BPX-01
Acne

Latest News

  1. BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel
  2. BioPharmX Completes Enrollment of BPX-01 Phase 2b OPAL Clinical Trial for Acne Vulgaris
  3. BIOPHARMX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  4. BIOPHARMX CORP Financials
  5. BioPharmX (BPMX) Exited Fiscal Third Quarter with Strong Balance Sheet
  6. BIOPHARMX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal Of
  7. BioPharmX Corporation Reports Third Quarter Financial Results
  8. ETFs with exposure to BioPharmX Corp. : December 13, 2016
  9. These 5 Stocks Under $10 Could Make You a Lot of Money
  10. BioPharmX to present evidence that BPX-01 topical minocycline gel may reduce acne-associated inflammation
  11. BioPharmX to Report Third Quarter Financial Results
  12. BioPharmX Presents Research at Cell Biology 2016 Showing How Molecular Iodine Promotes Breast Health by Attacking Fibrocystic Breast Tissue
  13. BIOPHARMX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  14. BioPharmX Corporation Announces Closing of a $12.5 Million Unit Offering
  15. BIOPHARMX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and
  16. BioPharmX Corporation Announces Pricing of Unit Offering
  17. BioPharmX Presents BPX-01 Topical Minocycline Gel Acne Data at SDEF's 17th Annual Las Vegas Dermatology Seminar
  18. BioPharmX Studies Suggest its Violet® Iodine Formulation Inhibits Growth of Both FBC and Common Breast Cancer Cells in vitro
  19. BIOPHARMX CORP Files SEC form 8-K, Change in Directors or Principal Officers
  20. BIOPHARMX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities